Editas Medicine Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
266
- Stock Symbol
-
EDIT
- Investments
-
1
- Share Price
-
$1.45
- (As of Friday Closing)
Editas Medicine General Information
Description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Contact Information
Website
www.editasmedicine.comCorporate Office
- 11 Hurley Street
- Cambridge, MA 02141
- United States
Corporate Office
- 11 Hurley Street
- Cambridge, MA 02141
- United States
Editas Medicine Stock Performance
As of 09-May-2025, Editas Medicine’s stock price is $1.45. Its current market cap is $121M with 83.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.45 | $1.39 | $0.91 - $6.69 | $121M | 83.7M | 3.65M | -$2.88 |
Editas Medicine Financials Summary
As of 31-Dec-2024, Editas Medicine has a trailing 12-month revenue of $32.3M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (121,764) | (121,764) | 512,348 | 211,611 |
| Revenue | 32,314 | 32,314 | 78,123 | 19,712 |
| EBITDA | (245,346) | (245,346) | (164,721) | (219,613) |
| Net Income | (237,093) | (237,093) | (153,219) | (220,432) |
| Total Assets | 341,589 | 341,589 | 499,153 | 514,321 |
| Total Debt | 35,032 | 35,032 | 36,536 | 43,946 |
Editas Medicine Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Editas Medicine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Editas Medicine Comparisons
Industry
Financing
Details
Editas Medicine Competitors (43)
One of Editas Medicine’s 43 competitors is Intellia Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Verve Therapeutics | Formerly VC-backed | Boston, MA | ||||
| EdiGene | Venture Capital-Backed | Beijing, China |
Editas Medicine Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Editas Medicine Patents
Editas Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240271161-A1 | Novel recombinases and methods of use | Pending | 16-Sep-2022 | ||
| AU-2023342387-A1 | Novel recombinases and methods of use | Pending | 16-Sep-2022 | ||
| EP-4522736-A2 | Genome editing of b cells | Pending | 10-May-2022 | ||
| EP-4522182-A2 | Genome editing of cells | Pending | 10-May-2022 | ||
| EP-4441209-A1 | Engineered crispr/cas12a effector proteins, and uses thereof | Pending | 29-Nov-2021 | A61K48/005 |
Editas Medicine Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Editas Medicine Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Editas Medicine Acquisitions (1)
Editas Medicine’s most recent deal was a Merger/Acquisition with i2 Pharmaceuticals for . The deal was made on 22-Jan-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| i2 Pharmaceuticals | 22-Jan-2018 | Merger/Acquisition | Drug Discovery |
Editas Medicine ESG
Risk Overview
Risk Rating
Updated February, 22, 2025
32.87 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Biotechnology
Subindustry
of 365
Rank
Percentile
Editas Medicine FAQs
-
When was Editas Medicine founded?
Editas Medicine was founded in 2013.
-
Where is Editas Medicine headquartered?
Editas Medicine is headquartered in Cambridge, MA.
-
What is the size of Editas Medicine?
Editas Medicine has 266 total employees.
-
What industry is Editas Medicine in?
Editas Medicine’s primary industry is Drug Discovery.
-
Is Editas Medicine a private or public company?
Editas Medicine is a Public company.
-
What is Editas Medicine’s stock symbol?
The ticker symbol for Editas Medicine is EDIT.
-
What is the current stock price of Editas Medicine?
As of 09-May-2025 the stock price of Editas Medicine is $1.45.
-
What is the current market cap of Editas Medicine?
The current market capitalization of Editas Medicine is $121M.
-
What is Editas Medicine’s current revenue?
The trailing twelve month revenue for Editas Medicine is $32.3M.
-
Who are Editas Medicine’s competitors?
Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences, Verve Therapeutics, and EdiGene are some of the 43 competitors of Editas Medicine.
-
What is Editas Medicine’s annual earnings per share (EPS)?
Editas Medicine’s EPS for 12 months was -$2.88.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
